Comprehensive Review: Understanding and Managing Interstitial Lung Diseases in Clinical Practice
OthersPage Navigation
Introduction
Interstitial Lung Diseases (ILDs) represent a heterogeneous group of more than 200 chronic lung disorders. Characterized by inflammation and fibrosis of the lung parenchyma, ILDs present significant diagnostic and therapeutic challenges.
Etiology and Pathogenesis
ILDs can be idiopathic or associated with various conditions such as connective tissue diseases, environmental exposures, or drug toxicity. The pathogenesis typically involves alveolar epithelial injury, leading to an aberrant repair process with fibroblast proliferation and extracellular matrix deposition.
Clinical Presentation and Diagnosis
Patients often present with progressive dyspnea and nonproductive cough. Physical examination may reveal crackles and finger clubbing. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, often showing reticular abnormalities and honeycombing. Lung biopsy may be necessary in certain cases.
Management
Management strategies are largely disease-specific and aim to alleviate symptoms, improve quality of life, and slow disease progression. They include general measures such as smoking cessation and vaccination, pharmacological therapy with corticosteroids and immunosuppressants, and in severe cases, lung transplantation.
Prognosis
Prognosis varies widely depending on the specific type of ILD, the severity at diagnosis, and the response to treatment. Idiopathic Pulmonary Fibrosis (IPF) has the worst prognosis, with a median survival of 2-3 years from diagnosis.
Conclusion
ILDs require a comprehensive, multidisciplinary approach for optimal patient management. Future research should focus on improving our understanding of the underlying pathophysiology and developing more effective treatments.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge